Delving into the Latest Updates on AVM0703 with Synapse

Overview

Basic Info

Drug Type

Natural Killer Cell Therapies

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

Ave Maria Biotechnology LLC

Active Organization

Ave Maria Biotechnology LLC

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.

Start Date01 Dec 2026

Sponsor / Collaborator

Ave Maria Biotechnology LLC

[+1]

NCT04329728

/ RecruitingPhase 1/2

An Open Label, Phase 1/2 Study Evaluating Immunomodulatory AVM0703 in Patients With Lymphoid Malignancies (OPAL Study)

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

Start Date06 Nov 2020

Sponsor / Collaborator

Ave Maria Biotechnology LLC

[+1]

100 Clinical Results associated with AVM0703

Login to view more data

100 Translational Medicine associated with AVM0703

Login to view more data

100 Patents (Medical) associated with AVM0703

Login to view more data

100 Deals associated with AVM0703

Login to view more data